Pre-tax profits at the main Irish unit of pharmaceutical giant Roche last year fell 8% to €10.39m.
New figures lodged with the Companies Office show that the Swiss-owned Roche Ireland Ltd sustained the drop in profits after revenues declined sharply going down 23% from €103m to €79.2m.
Numbers employed by the firm last year increased from 241 to 251.
The drop in revenues last year came in spite of production increasing by 9% at the 79-acre site in the Co Clare village of Clarecastle last year.
The plant last year said it was to start the production of Madapor that is used in the treatment of Parkinson’s and Zelboraf that is aimed at treating people with advanced melanoma skin cancer, at the plant.
Remuneration for the four directors employed by the firm last year increased from €342,096 to €359,039.
The profits last year take account of hefty non-cash depreciation costs of €11.5m and a loss of €607,224 on the sale of a fixed asset.
Underlining the continuing expansion at the plant, a note attached to the accounts states that at balance sheet date, capital expenditure amounting to €16.4m was approved by the directors.
Figures show the firm’s operating profits last year totalled €11.26m and this followed an operating profit of €12.4m in 2013.
The company had accumulated profits of €82.12m with shareholder funds totalling €90.3m. The firm’s cash increased from €463,207 to €527,549.
Staff costs at the firm last year increased by 4% from €24m to €25m — 237 are employed in production, seven in administration, and seven in management.
© Irish Examiner Ltd. All rights reserved